JOHNSON & JOHNSON · 2026-11-06 · Importance 44 · Surprise 24
Johnson & Johnson’s Innovative Medicine division contributed approximately 66% of total company revenue in the third quarter of 2026. The segment was described as the key driver of overall growth and delivered stronger performance than MedTech. Sales faced biosimilar and generic competition for Stelara, Remicade, and Zytiga.
Key facts
Johnson & Johnson’s Innovative Medicine segment contributed approximately 66% of the company’s total revenues in the third quarter. source
Johnson & Johnson’s Innovative Medicine segment faced biosimilar and generic competition headwinds for Stelara, Remicade and Zytiga. source